为了发现新型抗流感药物的来源,我们评估了八种药用植物和一种蘑菇的九种提取物的抗病毒潜力(AvenasativaL.,大麦。var.NudumHook.f.,沙棘林恩.,黑果枸杞.,NitrariatangutorumBobr.,NitrariatangutorumBobr.副产品,鹅色委陵菜,Cladinarangiferina(L.)尼尔。,来自青藏高原的蜜环菌和蜜环菌)对抗A/H3N2流感病毒。所有提取物的浓度低于125μg/mL表明在MDCK细胞中没有显著的毒性。在筛选过程中,七个提取物(A.sativa,H.vulgare,H.鼠李糖,L.ruthenicum,唐古托姆,C.rangiferina,和A.luteo-virens)表现出抗病毒活性,特别是来自蘑菇A.luteo-virens子实体的水溶性多糖。当以15.6-125μg/mL的浓度使用时,这些提取物在体外显著降低了人流感A/H3N2病毒的感染性。两个提取物(N.tangutorum副产物和P.anserina)没有A/H3N2病毒抑制活性。值得注意的是,从唐古特诺姆和唐古特诺姆副产品的果实中获得的提取物表现出不同的抗流感作用。结果表明,紫花苜蓿的提取物,H.vulgare,H.鼠李糖,L.ruthenicum,唐古托姆,C.rangiferina,和叶黄素含有具有抗病毒活性的物质,并且可能是新的抗病毒药物的有希望的来源。
To discover sources for novel anti-influenza drugs, we evaluated the antiviral potential of nine extracts from eight medicinal plants and one mushroom (Avena sativa L., Hordeum vulgare Linn. var. nudum Hook. f., Hippophae rhamnoides Linn., Lycium ruthenicum Murr., Nitraria tangutorum Bobr., Nitraria tangutorum Bobr. by-products, Potentilla anserina L., Cladina rangiferina (L.) Nyl., and Armillaria luteo-virens) from the Qinghai-Tibetan plateau against the influenza A/H3N2 virus. Concentrations lower than 125 μg/mL of all extracts demonstrated no significant toxicity in MDCK cells. During screening, seven extracts (A. sativa, H. vulgare, H. rhamnoides, L. ruthenicum, N. tangutorum, C. rangiferina, and A. luteo-virens) exhibited antiviral activity, especially the water-soluble polysaccharide from the fruit body of the mushroom A. luteo-virens. These extracts significantly reduced the infectivity of the human influenza A/H3N2 virus in vitro when used at concentrations of 15.6-125 μg/mL. Two extracts (N. tangutorum by-products and P. anserina) had no A/H3N2 virus inhibitory activity. Notably, the extract obtained from the fruits of N. tangutorum and N. tangutorum by-products exhibited different anti-influenza effects. The results suggest that extracts of A. sativa, H. vulgare, H. rhamnoides, L. ruthenicum, N. tangutorum, C. rangiferina, and A. luteo-virens contain substances with antiviral activity, and may be promising sources of new antiviral drugs.